Baird raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $252 from $209 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results which beat across all products driving iits robust bottom line.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals reports Q1 adjusted EPS $6.34, consensus $4.66
- Jazz Pharmaceuticals sees FY26 revenue $4.25B-$4.5B, consensus $4.45B
- JAZZ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Jazz Pharmaceuticals’ sBLA for Ziihera combination in GEA accepted by FDA
- Jazz Pharmaceuticals price target raised to $225 from $224 at Barclays